Skip to main content
Erschienen in: Supportive Care in Cancer 2/2008

01.02.2008 | Original Article

The influence of xerostomia after radiotherapy on quality of life

Results of a questionnaire in head and neck cancer

verfasst von: Piet Dirix, Sandra Nuyts, Vincent Vander Poorten, Pierre Delaere, Walter Van den Bogaert

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Xerostomia is a common complication of radiotherapy for head and neck cancer because irreparable damage is caused to the salivary glands if they are included in the radiation fields. The aim of the study was to evaluate the degree of xerostomia in survivors of head and neck cancer and to determine its impact on quality of life.

Methods and materials

A xerostomia questionnaire consisting of three parts (xerostomia score, quality of life survey, and visual analogue scale) was completed by 75 head and neck cancer patients, more than 6 months after radiotherapy and without evidence of disease.

Results

The majority of patients (93%) suffered from a dry mouth, and 65% had moderate to severe xerostomia (grade 2 to 3). Both dysphagia (65%) and taste loss (63%) were common, although oral pain was less frequent (33%). The emotional impact of xerostomia was significant, causing worry (64%), tension (61%), or feelings of depression (44%). Furthermore, patients reported problems with talking to (60%) or eating with (54%) other people and to feel restricted in amount and type of food (65%). Quality of life was influenced by T classification, clinical stage, a higher radiation dose or the use of concomitant chemotherapy, but was independent of the interval since the end of radiotherapy.

Conclusions

Xerostomia after radiotherapy for head and neck cancer is extremely common and significantly affects quality of life. No recuperation is seen over time, and the use of concomitant chemotherapy significantly increases the oral complications of radiation. These results warrant the continuing efforts put into the development of salivary gland-sparing radiotherapy techniques and effective treatments of radiation-induced xerostomia.
Literatur
1.
Zurück zum Zitat Bjordal K, Kaasa S, Mastekaasa A (1994) Quality of life in patients treated for head and neck cancer. Int J Radiat Oncol Biol Phys 28:847–856PubMed Bjordal K, Kaasa S, Mastekaasa A (1994) Quality of life in patients treated for head and neck cancer. Int J Radiat Oncol Biol Phys 28:847–856PubMed
2.
Zurück zum Zitat Bjordal K, Freng A, Thorvik J, Kaasa S (1995) Patient self-reported and clinician-rated quality of life in head and neck cancer patients: a cross-sectional study. Oral Oncol 31:235–241 Bjordal K, Freng A, Thorvik J, Kaasa S (1995) Patient self-reported and clinician-rated quality of life in head and neck cancer patients: a cross-sectional study. Oral Oncol 31:235–241
3.
Zurück zum Zitat Braam PM, Roesink JM, Moerland MA et al (2005) Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 62:659–664PubMedCrossRef Braam PM, Roesink JM, Moerland MA et al (2005) Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 62:659–664PubMedCrossRef
4.
Zurück zum Zitat Braam PM, Roesink JM, Raaijmakers C, Busschers W, Terhaard C (2007) Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiat Oncol 2:3PubMedCrossRef Braam PM, Roesink JM, Raaijmakers C, Busschers W, Terhaard C (2007) Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy. Radiat Oncol 2:3PubMedCrossRef
5.
Zurück zum Zitat Bussels B, Maes A, Flamen P et al (2004) Dose–response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 73:297–306PubMedCrossRef Bussels B, Maes A, Flamen P et al (2004) Dose–response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 73:297–306PubMedCrossRef
6.
Zurück zum Zitat Dirix P, Nuyts S, Van den Bogaert W (2006) Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 107(11):2525–2534PubMedCrossRef Dirix P, Nuyts S, Van den Bogaert W (2006) Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 107(11):2525–2534PubMedCrossRef
7.
Zurück zum Zitat Dirix P, Nuyts S, Vander Poorten V, Van den Bogaert W (2007) Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia. Support Care Cancer (in press; E-pub ahead of print) Dirix P, Nuyts S, Vander Poorten V, Van den Bogaert W (2007) Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia. Support Care Cancer (in press; E-pub ahead of print)
8.
Zurück zum Zitat Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, Pater J (2005) Quality of life, mucositis and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucostis. Head Neck 27:421–428PubMedCrossRef Duncan GG, Epstein JB, Tu D, El Sayed S, Bezjak A, Ottaway J, Pater J (2005) Quality of life, mucositis and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucostis. Head Neck 27:421–428PubMedCrossRef
9.
Zurück zum Zitat Eisbruch A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13:226–234PubMedCrossRef Eisbruch A, Rhodus N, Rosenthal D et al (2003) How should we measure and report radiotherapy-induced xerostomia? Semin Radiat Oncol 13:226–234PubMedCrossRef
11.
Zurück zum Zitat Epstein JB, Emerton S, Kolbinson DA et al (1999) Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 21:1–11PubMedCrossRef Epstein JB, Emerton S, Kolbinson DA et al (1999) Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 21:1–11PubMedCrossRef
12.
Zurück zum Zitat Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P (2001) Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23:389–398PubMedCrossRef Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P (2001) Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23:389–398PubMedCrossRef
13.
Zurück zum Zitat Guchelaar H, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288PubMedCrossRef Guchelaar H, Vermes A, Meerwaldt JH (1997) Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 5:281–288PubMedCrossRef
14.
Zurück zum Zitat Harrison L, Zelefski M, Pfitzer D et al (1997) Detailed quality of life assessment in patients treated with primary radiotherapy for cancer of the base of tongue. Head Neck 19:169–175PubMedCrossRef Harrison L, Zelefski M, Pfitzer D et al (1997) Detailed quality of life assessment in patients treated with primary radiotherapy for cancer of the base of tongue. Head Neck 19:169–175PubMedCrossRef
15.
Zurück zum Zitat Hassan SJ, Weymuller EA (1993) Assessment of quality of life in head and neck cancer patients. Head Neck 15:485–496PubMedCrossRef Hassan SJ, Weymuller EA (1993) Assessment of quality of life in head and neck cancer patients. Head Neck 15:485–496PubMedCrossRef
16.
Zurück zum Zitat Henk JM (1997) Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol 9:308–312CrossRef Henk JM (1997) Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol 9:308–312CrossRef
17.
Zurück zum Zitat Hoopman R, Muller MJ, Terwee CB, Aaronson NK (2006) Translation and validation of the EORTC QLQ-C30 for use among Turkish and Moroccan ethnic minority cancer patients in the Netherlands. Eur J Cancer 42(12):1839–1847PubMedCrossRef Hoopman R, Muller MJ, Terwee CB, Aaronson NK (2006) Translation and validation of the EORTC QLQ-C30 for use among Turkish and Moroccan ethnic minority cancer patients in the Netherlands. Eur J Cancer 42(12):1839–1847PubMedCrossRef
18.
19.
Zurück zum Zitat Long SA, D’Antonio LL, Robinson EB, Zimmerman G, Petti G, Chonkich G (1996) Factors related to quality of life and functional status in 50 patients with head and neck cancer. Laryngoscope 106:1084–1088PubMedCrossRef Long SA, D’Antonio LL, Robinson EB, Zimmerman G, Petti G, Chonkich G (1996) Factors related to quality of life and functional status in 50 patients with head and neck cancer. Laryngoscope 106:1084–1088PubMedCrossRef
20.
Zurück zum Zitat Maes A, Weltens C, Flamen P et al (2002) Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 63:203–211PubMedCrossRef Maes A, Weltens C, Flamen P et al (2002) Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 63:203–211PubMedCrossRef
21.
Zurück zum Zitat Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 66(2):445–453PubMed Meirovitz A, Murdoch-Kinch CA, Schipper M, Pan C, Eisbruch A (2006) Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys 66(2):445–453PubMed
22.
Zurück zum Zitat Meyer TK, Kuhn JC, Campbell BH et al (2004) Speech intelligibility and quality of life in head and neck survivors. Laryngoscope 114:1977–1981PubMedCrossRef Meyer TK, Kuhn JC, Campbell BH et al (2004) Speech intelligibility and quality of life in head and neck survivors. Laryngoscope 114:1977–1981PubMedCrossRef
23.
Zurück zum Zitat Nieuw Amerongen AV, Veerman ECI (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11:226–231PubMed Nieuw Amerongen AV, Veerman ECI (2003) Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer 11:226–231PubMed
24.
Zurück zum Zitat Roesink J, Schipper M, Busschers W, Raaijmakers C, Terhaard C (2005) A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. Int J Radiat Oncol Biol Phys 63:1006–1009PubMedCrossRef Roesink J, Schipper M, Busschers W, Raaijmakers C, Terhaard C (2005) A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. Int J Radiat Oncol Biol Phys 63:1006–1009PubMedCrossRef
25.
Zurück zum Zitat Thoeny H, De Keyzer F, Claus F, Sunaert S, Hermans R (2005) Gustatory stimulation changes the apparent diffusion coefficient of salivary glands: initial experience. Radiology 235:629–634PubMedCrossRef Thoeny H, De Keyzer F, Claus F, Sunaert S, Hermans R (2005) Gustatory stimulation changes the apparent diffusion coefficient of salivary glands: initial experience. Radiology 235:629–634PubMedCrossRef
26.
Zurück zum Zitat Van Acker F, Flamen P, Lambin P et al (2001) The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Common 22:225–231CrossRef Van Acker F, Flamen P, Lambin P et al (2001) The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nucl Med Common 22:225–231CrossRef
27.
Zurück zum Zitat Weymuller EA, Yueh B, Deleyiannis F et al (2000) Quality of life in head and neck cancer. Laryngoscope 110(Suppl 94):4–7PubMedCrossRef Weymuller EA, Yueh B, Deleyiannis F et al (2000) Quality of life in head and neck cancer. Laryngoscope 110(Suppl 94):4–7PubMedCrossRef
28.
Zurück zum Zitat Weymuller EA, Yueh B, Deleyiannis F et al (2000) Quality of life in patients with head and neck cancer. Lessons learned from 549 prospectively evaluated patients. Arch Otolaryngol Head Neck Surg 126:329–335PubMed Weymuller EA, Yueh B, Deleyiannis F et al (2000) Quality of life in patients with head and neck cancer. Lessons learned from 549 prospectively evaluated patients. Arch Otolaryngol Head Neck Surg 126:329–335PubMed
29.
Zurück zum Zitat Wijers O, Levendag P, Braaksma M, Boonzaaijer M, Visch L, Schmitz P (2002) Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 24:737–747PubMedCrossRef Wijers O, Levendag P, Braaksma M, Boonzaaijer M, Visch L, Schmitz P (2002) Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck 24:737–747PubMedCrossRef
Metadaten
Titel
The influence of xerostomia after radiotherapy on quality of life
Results of a questionnaire in head and neck cancer
verfasst von
Piet Dirix
Sandra Nuyts
Vincent Vander Poorten
Pierre Delaere
Walter Van den Bogaert
Publikationsdatum
01.02.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0300-5

Weitere Artikel der Ausgabe 2/2008

Supportive Care in Cancer 2/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.